News

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

A newly-published study identified specific groups of higher-risk children that could benefit most from monoclonal antibodies.

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

A week into July 2025, the total reported cases in the United States have surpassed the peak of 1274 cases recorded for all 2019.

Six medical societies, including the American Academy of Pediatrics, are suing the HHS and its Secretary to "defend vaccine policy."

Though the original target action date was not met by the FDA, KalVista's sebetralstat is now approved to treat HAE in patients 12 years and older.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

A roundup of the most impactful FDA approvals in pediatric health from January through June 2025, spanning diagnostics, therapeutics, and at-home care.

A look back at the most important FDA approvals, clinical research, and expert perspectives shaping pediatric health care in the first half of 2025.

View our Q2 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Additionally, long sleep duration could be associated with increased odds of being reliably symptomatic at 4 weeks.

Data from the study suggest caretakers of CPP patients be vigilant for psychiatric symptoms to begin care at an early stage.

Take a quick look at everything you may have missed last month, including the top FDA approvals and latest clinical updates.

The revised labeling will warn that patients younger than 6 years taking these medications are at greater risk of weight loss.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from June 2025.

The updated labeling includes a new contraindication for patients with prior or active hepatic events.

MNV-201 is being evaluated in phase 2 clinical trials for treatment of the ultra-rare, life-threatening mitochondrial disorder affecting children.

The total number of pediatric mental health hospitalizations declined in 2022, the first time observed since 2009.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Roflumilast cream 0.05% is being studied for mild to moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.

New phase 3 data support marstacimab’s efficacy and safety in treating hemophilia A or B with inhibitors, expanding its potential use.

Mycoplasma pneumoniae caused 1 in 2 pediatric pneumonia hospitalizations in 2024, with sharp increases seen across all age groups, according to a recent CDC MMWR report.

The final recommendation sign off decision will go to HHS secretary Robert F. Kennedy Jr.

Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate to severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.

The American Academy of Pediatrics will continue to hold its own childhood vaccine schedule, as it has since the 1930s.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on how PNPs can implement evidence-based strategies to encourage parents to vaccinate their children.

Silver diamine fluoride and atraumatic restorative treatment stopped most cavities in NYC children, showing school-based care can reduce decay.

The FDA has approved belimumab (Benlysta; GSK) autoinjector for children with lupus nephritis, expanding at-home treatment.